Valenzano A, Tartaglia N, Ambrosi A, Tafuri D, Monda M, Messina A, et al
DIRKO) mice, but not in Glp1r / mice (Flock et al., 2013) (Figure 2)
Pellati D, Mylonakis I, Bertoloni G, Fiore C, Andrisani A, Ambrosini G, et al
Medical Inclusions: Mounjaro 2.5mg Injection 4 doses (Weeks 14) Mounjaro 5mg Injection 4 doses (Weeks 58) Administration of Medication (clinic-supervised injection) Storage of Medication (cold chain maintained at the clinic) Guaranteed Stock Availability Medical Monitoring Follow-up and side effect check-in within the 8-week program period (does not include additional laboratory tests
Researchers used a tranche of data from patients who had been prescribed a GLP-1 for diabetes or obesity between 2021-2022